Antiretroviral Therapy 2012: Current and Future Perspectives (Pathogenesis Driven ART)
Sorry, this learning module is not available for mobile devices.
Scott Hammer, MD
Harold C. Neu Professor of Medicine and Chief, Division of Infectious Diseases
Columbia University Medical Center/New York-Presbyterian Hospital
Presentation Date: 5/25/2012
Release Date: 6/21/2012
- Discuss the current approach to antiretroviral therapy for HIV infection.
- Explain advantages and disadvantages of regimens for initial therapy of HIV-1 infection.
- Describe the approach to treatment in patients who develop drug-resistant HIV-1.
- Discuss the future directions of antiretroviral therapy.
Dr. Hammer’s major investigative interest is the treatment and prevention of HIV disease. He is an investigator in the National Institutes of Health sponsored AIDS Clinical Trials Group (ACTG). Dr. Hammer is also an investigator in the National Institutes of Health sponsored HIV Vaccine Trials Network (HVTN), a multicenter organization whose mission is to develop an effective preventive HIV vaccine. He is the current protocol chair of HVTN 505, an advanced phase II study of the preventive HIV vaccine regimen developed by NIAID’s Vaccine Research Center. He is a former Chair of the AIDS Vaccine Research Working Group of the Division of AIDS, NIAID, and the Antiviral Products Advisory Committee of the Food and Drug Administration and currently serves on the Editorial Board of the New England Journal of Medicine. Dr. Hammer is a former Chair of the International AIDS Society-USA’s Antiretroviral Guidelines Panel and former Vice Chair of the World Health Organization’s Strategic and Technical Advisory Committee for HIV/AIDS. He chaired the Guidelines Development Group of the WHO’s Antiretroviral Guidelines for Resource Limited Settings in 2002, 2003 and 2006 and co-chaired the Steering Committee of the WHO’s Global HIV Drug Resistance Surveillance Program. In his role as Chief of the Division of Infectious Diseases at CUMC, he is dedicated to fellow and faculty growth and to the development of state-of-the-art infection surveillance at the institutional and regional levels to improve and protect the public health.